Overview

Efficacy and Safety of TAK-653 in Treatment-Resistant Depression

Status:
Withdrawn
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Ketamine